Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936520 · ClinicalTrials.gov registry record · Phase 1
SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy
A Phase 1 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00936520: Clinical Trial Phase 1 study, sponsored by Johns Hopkins University.
NCT00936520 is a Phase 1 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00936520, a Phase 1 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of SAR 1118 within the anterior and posterior chamber of the eye and plasma in subjects undergoing elective vitrectomy when treated with escalating concentrations of the study drug for approximately 1 week.
Interventions
- DRUG SAR 1118 0.1%
- DRUG SAR 1118 1.0%
- DRUG SAR 1118 5.0%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00936520
The ClinicalTrials.gov registry entry for NCT00936520 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SAR 1118 0.1% is the first listed.
NCT00936520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00936520 about?
NCT00936520 is a clinical study titled "SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy". The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of SAR 1118 within the anterior and posterior chamber of the eye and plasma in subjects undergoing elective vitrectomy when treated with escalating concentrations of the study drug for approximately 1 week.
What is the current status of trial NCT00936520?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2009-08. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00936520?
The interventions under investigation include: SAR 1118 0.1% (DRUG), SAR 1118 1.0% (DRUG), SAR 1118 5.0% (DRUG).
Who is sponsoring clinical trial NCT00936520?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.